H
HLB Life Science Co Ltd
KOSDAQ:067630
HLB Life Science Co Ltd
KOSDAQ:067630
Price:
4 850
KRW
12.79%
Market Closed
Market Cap:
₩591.3B
Relative Value
The Relative Value of one HLB Life Science Co Ltd stock under the Base Case scenario is 2 563.5 KRW. Compared to the current market price of 4 850 KRW, HLB Life Science Co Ltd is Overvalued by 47%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
2 563.5
KRW
Overvaluation 47%
H
Multiples Across Competitors
Competitors Multiples
HLB Life Science Co Ltd Competitors
HLB Life Science Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
H
|
HLB Life Science Co Ltd
KOSDAQ:067630
|
523.9B KRW | 6.4 | -2.9 | -31.4 | -24.9 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
116B USD | 0.3 | 26.7 | 18.8 | 21.1 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
67.9B USD | 0.2 | 41.8 | 14.7 | 18.6 | |
| US |
|
Cencora Inc
NYSE:COR
|
67.3B USD | 0.2 | 41.5 | 14.6 | 18.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
51.4B USD | 0.2 | 30.9 | 14.9 | 19.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
30.5B AUD | 2.7 | 33.6 | 25 | 25 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64.3B CNY | 0.2 | 11.4 | 15.3 | 15.3 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
62.2B CNY | 1.4 | 16.8 | 13 | 13 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 0.7 | 21.7 | 10.5 | 14.8 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
67.2B HKD | 0.1 | 8.7 | 1.6 | 2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.9 | 89.6 | 59.9 | 61.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
